CRISPR-Based Treatment for Sickle Cell Disease and Thalassemia

This chapter discusses the first regulatory approved CRISPR-based treatment for sickle cell disease and transfusion-dependent beta thalassemia. It explains the background of these diseases and how they are caused by mutations in the hemoglobin gene. The chapter explores the process and potential risks of using CRISPR technology to treat these genetic diseases.